Bifidobacterium animalis ssp. lactis CNCM-I2494 restores gut barrier permeability in chronically low-grade inflamed mice

Frontiers in Microbiology

Volumn 7, Issue MAY, 2016, Pages

  Martín, Rebeca ^a   Laval, Laure ^a,b   Chain, Florian ^a   Miquel, Sylvie ^a,f   Natividad, Jane ^c   Cherbuy, Claire ^a   Sokol, Harry ^a,d,e   Verdu, Elena F ^c   Van Hylckama Vlieg, Johan ^b,g   Bermudez Humaran, Luis G ^a   Smokvina, Tamara ^b   Langella, Philippe ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b Groupe Danone   (France)

^c MCMASTER UNIVERSITY   (Canada)

^d Centre National de la Recherche Scientifique   (France)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^f UNIVERSITÉ CLERMONT AUVERGNE   (France)

^g CHR HANSEN A S   (Denmark)

Author keywords

Apical junction proteins; Goblet cells; Micro inflammation

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 5;

ANIMAL TISSUE; ARTICLE; BACTERIAL GROWTH; BIFIDOBACTERIUM ANIMALIS; CELL POPULATION; CONTROLLED STUDY; FLOW CYTOMETRY; HISTOLOGY; IMMUNE RESPONSE; INTESTINE FLORA; MOUSE; NONHUMAN; PERMEABILITY BARRIER; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TH1 TH2 BALANCE; TIGHT JUNCTION; WEIGHT REDUCTION;

EID: 84973462700     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2016.00608     Document Type: Article

References (44)

1. Agostini, S., Goubern, M., Tondereau, V., Salvador-Cartier, C., Bezirard, V., Leveque, M., et al. (2012). A marketed fermented dairy product containing Bifidobacterium lactis CNCM I-2494 suppresses gut hypersensitivity and colonic barrier disruption induced by acute stress in rats. Neurogastroenterol. Motil. 24:e172. doi: 10.1111/j.1365-2982.2011.01865.x
2. Agrawal, A., Houghton, L. A., Morris, J., Reilly, B., Guyonnet, D., Goupil Feuillerat, N., et al. (2009). Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. Aliment. Pharmacol. Ther. 29, 104-114. doi: 10.1111/j.1365-2036.2008.03853.x
3. Barbara, G., Zecchi, L., Barbaro, R., Cremon, C., Bellacosa, L., Marcellini, M., et al. (2012). Mucosal permeability and immune activation as potential therapeutic targets of probiotics in irritable bowel syndrome. J. Clin. Gastroenterol. 46(Suppl.), S52-S55. doi: 10.1097/MCG.0b013e318264e91800004836-201210001-00012
4. Bruewer, M., Utech, M., Ivanov, A. I., Hopkins, A. M., Parkos, C. A., and Nusrat, A. (2005). Interferon-gamma induces internalization of epithelial tight junction proteins via a macropinocytosis-like process. FASEB J 19, 923-933. doi: 10.1096/fj.04-3260com
5. Camilleri, M., Lasch, K., and Zhou, W. (2012). Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome. Am. J. Physiol. Gastrointest. Liver Physiol. 303, 775-785. doi: 10.1152/ajpgi.00155.2012
6. Chervaux, C., Grimaldi, C., Bolotin, A., Quinquis, B., Legrain-Raspaud, S., van Hylckama Vlieg, J. E., et al. (2011). Genome sequence of the probiotic strain Bifidobacterium animalis subsp. lactis CNCM I-2494. J. Bacteriol. 193, 5560-5561. doi: 10.1128/JB.05716-11
7. Denker, B. M., and Nigam, S. K. (1998). Molecular structure and assembly of the tight junction. Am. J. Physiol. Renal Physiol. 274, 1-9.
8. Distrutti, E., Cipriani, S., Mencarelli, A., Renga, B., and Fiorucci, S. (2013). Probiotics VSL#3 protect against development of visceral pain in murine model of irritable bowel syndrome. PLoS ONE 8:e63893. doi: 10.1371/journal.pone.0063893
9. Donato, K. A., Gareau, M., Wang, Y. J., and Sherman, P. M. (2010). Lactobacillus rhamnosus GG attenuates interferon-γ and tumour necrosis factor-alpha-induced barrier dysfunction and pro-inflammatory signalling. Microbiology 156, 3288-3297. doi: 10.1099/mic.0.040139-0
10. Fyderek, K., Strus, M., Kowalska-Duplaga, K., Gosiewski, T., Wedrychowicz, A., Jedynak-Wasowicz, U., et al. (2009). Mucosal bacterial microflora and mucus layer thickness in adolescents with inflammatory bowel disease. World J Gastroenterol 15, 5287-5294. doi: 10.3748/wjg.15.5287
11. Gaudier, E., Jarry, A., Blottiere, H. M., de Coppet, P., Buisine, M. P., Aubert, J. P., et al. (2004). Butyrate specifically modulates MUC gene expression in intestinal epithelial goblet cells deprived of glucose. Am. J. Physiol. Gastrointest. Liver Physiol. 287, G1168-G1174. doi: 10.1152/ajpgi.00219.2004
12. Gaudier, E., Michel, C., Segain, J. P., Cherbut, C., and Hoebler, C. (2005). The VSL# 3 probiotic mixture modifies microflora but does not heal chronic dextran-sodium sulfate-induced colitis or reinforce the mucus barrier in mice. J. Nutr. 135, 2753-2761.
13. Guyonnet, D., Schlumberger, A., Mhamdi, L., Jakob, S., and Chassany, O. (2009a). Fermented milk containing Bifidobacterium lactis DN-173 010 improves gastrointestinal well-being and digestive symptoms in women reporting minor digestive symptoms: a randomised, double-blind, parallel, controlled study. Br. J. Nutr. 102, 1654-1662. doi: 10.1017/S0007114509990882
14. Guyonnet, D., Woodcock, A., Stefani, B., Trevisan, C., and Hall, C. (2009b). Fermented milk containing Bifidobacterium lactis DN-173 010 improved self-reported digestive comfort amongst a general population of adults. A randomized, open-label, controlled, pilot study. J. Dig. Dis. 10, 61-70. doi: 10.1111/j.1751-2980.2008.00366.x
15. He, F., Ouwehan, A. C., Hashimoto, H., Isolauri, E., Benno, Y., and Salminen, S. (2001). Adhesion of Bifidobacterium spp. to human intestinal mucus. Microbiol. Immunol. 45, 259-262. doi: 10.1111/j.1348-0421.2001.tb02615.x
16. Laval, L., Martin, R., Natividad, J., Chain, F., Miquel, S., de Maredsous, C. D., et al. (2015). Lactobacillus rhamnosus CNCM I-3690 and the commensal bacterium Faecalibacterium prausnitzii A2-165 exhibit similar protective effects to induced barrier hyper-permeability in mice. Gut Microbes 6, 1-9. doi: 10.4161/19490976.2014.990784
17. Lepercq, P., Relano, P., Cayuela, C., and Juste, C. (2004). Bifidobacterium animalis strain DN-173 010 hydrolyses bile salts in the gastrointestinal tract of pigs. Scand. J. Gastroenterol. 39, 1266-1271. doi: 10.1080/00365520410003515
18. Lopetuso, L. R., Scaldaferri, F., Bruno, G., Petito, V., Franceschi, F., and Gasbarrini, A. (2015). The therapeutic management of gut barrier leaking: the emerging role for mucosal barrier protectors. Eur. Rev. Med. Pharmacol. Sci. 19, 1068-1076.
19. Lopez, P., Gonzalez-Rodriguez, I., Gueimonde, M., Margolles, A., and Suarez, A. (2011). Immune response to Bifidobacterium bifidum strains support Treg/Th17 plasticity. PLoS ONE 6:e24776. doi: 10.1371/journal.pone.0024776
20. Marteau, P., Cuillerier, E., Meance, S., Gerhardt, M. F., Myara, A., Bouvier, M., et al. (2002). Bifidobacterium animalis strain DN-173 010 shortens the colonic transit time in healthy women: a double-blind, randomized, controlled study. Aliment. Pharmacol. Ther. 16, 587-593. doi: 10.1046/j.1365-2036.2002.01188.x
21. Marteau, P., Guyonnet, D., Lafaye, de Micheaux, P., and Gelu, S. (2013). A randomized, double-blind, controlled study and pooled analysis of two identical trials of fermented milk containing probiotic Bifidobacterium lactis CNCM I-2494 in healthy women reporting minor digestive symptoms. Neurogastroenterol. Motil. 25:e252. doi: 10.1111/nmo.12078
22. Martin, R., Chain, F., Miquel, S., Lu, J., Gratadoux, J. J., Sokol, H., et al. (2014). The Commensal Bacterium Faecalibacterium prausnitzii is protective in DNBS-induced chronic moderate and severe colitis models. Inflamm. Bowel. Dis. 20, 417-430. doi: 10.1097/01.MIB.0000440815.76627.64
23. Martin, R., Miquel, S., Chain, F., Natividad, J. M., Jury, J., Lu, J., et al. (2015). Faecalibacterium prausnitzii prevents physiological damages in a chronic low-grade inflammation murine model. BMC Microbiol. 15:67. doi: 10.1186/s12866-015-0400-1
24. Mennigen, R., Nolte, K., Rijcken, E., Utech, M., Loeffler, B., Senninger, N., et al. (2009). Probiotic mixture VSL#3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 296, 1140-1149. doi: 10.1152/ajpgi.90534.2008
25. Natividad, J. M., Hayes, C. L., Motta, J. P., Jury, J., Galipeau, H. J., Philip, V., et al. (2013). Differential induction of antimicrobial REGIII by the intestinal microbiota and Bifidobacterium breve NCC2950. Appl. Environ. Microbiol. 79, 7745-7754. doi: 10.1128/AEM.02470-13
26. Natividad, J. M., and Verdu, E. F. (2013). Modulation of intestinal barrier by intestinal microbiota: pathological and therapeutic implications. Pharmacol. Res. 69, 42-51. doi: 10.1016/j.phrs.2012.10.007
27. O'Connell Motherway, M., Watson, D., Bottacini, F., Clark, T. A., Roberts, R. J., Korlach, J., et al. (2014). Identification of restriction-modification systems of Bifidobacterium animalis subsp. lactis CNCM I-2494 by SMRT sequencing and associated methylome analysis. PLoS ONE 9:e94875. doi: 10.1371/journal.pone.0094875
28. Ohman, L., and Simren, M. (2007). New insights into the pathogenesis and pathophysiology of irritable bowel syndrome. Dig. Liver Dis. 39, 201-215. doi: 10.1016/j.dld.2006.10.014
29. Perrier, C., and Corthésy, B. (2011). Gut permeability and food allergies. Clin. Exp. Allergy 41, 20-28. doi: 10.1111/j.1365-2222.2010.03639.x
30. Picard, C., Fioramonti, J., Francois, A., Robinson, T., Neant, F., and Matuchansky, C. (2005). Review article: bifidobacteria as probiotic agents-physiological effects and clinical benefits. Aliment. Pharmacol. Ther. 22, 495-512. doi: 10.1111/j.1365-2036.2005.02615.x
31. Prasad, S., Mingrino, R., Kaukinen, K., Hayes, K. L., Powell, R. M., MacDonald, T. T., et al. (2005). Inflammatory processes have differential effects on claudins 2, 3 and 4 in colonic epithelial cells. Lab. Invest 85, 1139-1162. doi: 10.1038/labinvest.3700316
32. Rochet, V., Rigottier-Gois, L., Ledaire, A., Andrieux, C., Sutren, M., Rabot, S., et al. (2008). Survival of Bifidobacterium animalis DN-173 010 in the faecal microbiota after administration in lyophilised form or in fermented product-a randomised study in healthy adults. J. Mol. Microbiol. Biotechnol. 14, 128-136. doi: 10.1159/000106092
33. Shashidharamurthy, R., Machiah, D., Aitken, J. D., Putty, K., Srinivasan, G., Chassaing, B., et al. (2013). Differential role of lipocalin 2 during immune complex-mediated acute and chronic inflammation in mice. Arthritis Rheum. 65, 1064-1073. doi: 10.1002/art.37840
34. Suzuki, T., Yoshinaga, N., and Tanabe, S. (2011). Interleukin-6 (IL-6) regulates claudin-2 expression and tight junction permeability in intestinal epithelium. J. Biol. Chem. 286, 31263-31271. doi: 10.1074/jbc. M111.238147
35. Tambuwala, M. M., Cummins, E. P., Lenihan, C. R., Kiss, J., Stauch, M., Scholz, C. C., et al. (2010). Loss of prolyl hydroxylase-1 protects against colitis through reduced epithelial cell apoptosis and increased barrier function. Gastroenterology 139, 2093-2101. doi: 10.1053/j.gastro.2010.06.068
36. Tavan, E., Cayuela, C., Antoine, J. M., Trugnan, G., Chaugier, C., and Cassand, P. (2002). Effects of dairy products on heterocyclic aromatic amine-induced rat colon carcinogenesis. Carcinogenesis 23, 477-483. doi: 10.1093/carcin/23.3.477
37. Ukena, S. N., Anurag, S., Dringenberg, U., Engelhardt, R., Seidler, U., Hansen, W., et al. (2007). Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity. PLoS ONE 2:e1308. doi: 10.1371/journal.pone.0001308
38. Vaarala, O. (2012). Is the origin of type 1 diabetes in the gut? Immunol. Cell Biol. 90, 271-276. doi: 10.1038/icb.2011.115
39. Veiga, P., Gallini, C. A., Beal, C., Michaud, M., Delaney, M. L., DuBois, A., et al. (2010). Bifidobacterium animalis subsp. lactis fermented milk product reduces inflammation by altering a niche for colitogenic microbes. Proc. Natl. Acad. Sci. U.S.A. 107, 18132-18137. doi: 10.1073/pnas.1011737107
40. Wisner, D. M., Harris, L. R., Green, C. L., and Poritz, L. S. (2008). Opposing regulation of the tight junction protein claudin-2 by interferon-gamma and interleukin-4. J. Surg. Res. 144, 1-7. doi: 10.1016/j.jss.2007.03.059
41. Wrzosek, L., Miquel, S., Noordine, M. L., Bouet, S., Joncquel Chevalier-Curt, M., Robert, V., et al. (2013). Bacteroides thetaiotaomicron and Faecalibacterium prausnitzii influence the production of mucus glycans and the development of goblet cells in the colonic epithelium of a gnotobiotic model rodent. BMC Biol. 11:61. doi: 10.1186/1741-7007-11-61
42. Zheng, B., van Bergenhenegouwen, J., Overbeek, S., van de Kant, H. J., Garssen, J., Folkerts, G., et al. (2014). Bifidobacterium breve attenuates murine dextran sodium sulfate-induced colitis and increases regulatory T cell responses. PLoS ONE 9:e95441. doi: 10.1371/journal.pone.0095441
43. Zhu, J., and Paul, W. E. (2008). CD4 T cells: fates, functions, and faults. Blood 112, 1557-1569. doi: 10.1182/blood-2008-05-078154
44. Zuo, L., Yuan, K. T., Yu, L., Meng, Q. H., Chung, P. C., and Yang, D. H. (2014). Bifidobacterium infantis attenuates colitis by regulating T cell subset responses. World J. Gastroenterol. 20, 18316-18329. doi: 10.3748/wjg.v20.i48.18316